Search results
Showing 571 to 585 of 838 results for score
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Tegaderm CHG securement dressing for vascular access sites (MIB231)
NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .
This quality standard covers diagnosing and managing cystic fibrosis in infants, children, young people and adults. It describes high-quality care in priority areas for improvement.
This quality standard covers assessing and managing oesophago-gastric cancer in adults. It describes high-quality care in priority areas for improvement.
NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .
NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.
View recommendations for MTG56Show all sections
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)
Evidence-based recommendations on darvadstrocel (Alofisel) for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease.
Rheumatoid arthritis: cardiovascular risk assessment (IND108)
This indicator covers the percentage of patients with rheumatoid arthritis (RA) aged 30 to 84 years who have had a cardiovascular risk assessment using a cardiovascular disease (CVD) risk assessment tool adjusted for RA in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM56